These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 9668542

  • 1. Long-term trials of deferiprone in Cooley's anemia.
    Olivieri NF, Brittenham GM.
    Ann N Y Acad Sci; 1998 Jun 30; 850():217-22. PubMed ID: 9668542
    [Abstract] [Full Text] [Related]

  • 2. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ.
    J Cardiovasc Magn Reson; 2008 Feb 25; 10(1):12. PubMed ID: 18298856
    [Abstract] [Full Text] [Related]

  • 3. Iron-chelation therapy with oral deferiprone in patients with thalassemia major.
    Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G.
    N Engl J Med; 1995 Apr 06; 332(14):918-22. PubMed ID: 7877649
    [Abstract] [Full Text] [Related]

  • 4. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Kontoghiorghes GJ, Kolnagou A.
    Lancet; 2003 Jan 11; 361(9352):184. PubMed ID: 12531621
    [No Abstract] [Full Text] [Related]

  • 5. Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
    Yatmark P, Morales NP, Chaisri U, Wichaiyo S, Hemstapat W, Srichairatanakool S, Svasti S, Fucharoen S.
    Exp Toxicol Pathol; 2014 Sep 11; 66(7):333-43. PubMed ID: 24907196
    [Abstract] [Full Text] [Related]

  • 6. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Res (Stuttg); 2017 Jul 11; 67(7):404-411. PubMed ID: 28320041
    [Abstract] [Full Text] [Related]

  • 7. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A, Felisi M, De Sanctis V, De Mattia D.
    Expert Opin Pharmacother; 2003 Oct 11; 4(10):1763-74. PubMed ID: 14521486
    [Abstract] [Full Text] [Related]

  • 8. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A, Kontoghiorghes GJ.
    Hemoglobin; 2006 Oct 11; 30(2):239-49. PubMed ID: 16798649
    [Abstract] [Full Text] [Related]

  • 9. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA.
    N Engl J Med; 1998 Aug 13; 339(7):417-23. PubMed ID: 9700174
    [Abstract] [Full Text] [Related]

  • 10. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    St Pierre TG.
    Lancet; 2003 Jan 11; 361(9352):182; author reply 183-4. PubMed ID: 12531617
    [No Abstract] [Full Text] [Related]

  • 11. New chelation therapies and emerging chelating drugs for the treatment of iron overload.
    Kontoghiorghes GJ.
    Expert Opin Emerg Drugs; 2006 Mar 11; 11(1):1-5. PubMed ID: 16503822
    [Abstract] [Full Text] [Related]

  • 12. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 13. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.
    Hemoglobin; 2008 Apr 10; 32(1-2):29-34. PubMed ID: 18274980
    [Abstract] [Full Text] [Related]

  • 14. Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
    Kolnagou A, Natsiopoulos K, Kleanthous M, Ioannou A, Kontoghiorghes GJ.
    Toxicol Mech Methods; 2013 Jan 10; 23(1):48-56. PubMed ID: 22943064
    [Abstract] [Full Text] [Related]

  • 15. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.
    Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V.
    J Cardiovasc Magn Reson; 2009 Jun 28; 11(1):20. PubMed ID: 19558722
    [Abstract] [Full Text] [Related]

  • 16. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep 28; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 17. Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study.
    Galia M, Midiri M, Bartolotta V, Morabito A, Rizzo M, Mangiagli A, Malizia R, Borsellino Z, Capra M, D'Ascola DG, Magnano C, Gerardi C, Rigano P, Maggio A, Multicenter Trial Group of the Society for the Study of Thalassemia and Haemoglobinopathies.
    Hemoglobin; 2003 May 28; 27(2):63-76. PubMed ID: 12779268
    [Abstract] [Full Text] [Related]

  • 18. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Fischer R, Engelhardt R.
    Lancet; 2003 Jan 11; 361(9352):182-3; author reply 183-4. PubMed ID: 12531618
    [No Abstract] [Full Text] [Related]

  • 19. Iron chelation with oral deferiprone in patients with thalassemia.
    Cohen AR, Martin MB.
    N Engl J Med; 1998 Dec 03; 339(23):1713-4. PubMed ID: 9867542
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
    Kolnagou A, Kleanthous M, Kontoghiorghes GJ.
    Hemoglobin; 2011 Dec 03; 35(3):186-98. PubMed ID: 21599431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.